Gan & Lee Pharmaceuticals Co., Ltd. (stock abbreviation: Gan & Lee Pharmaceuticals, stock code: 603087.SH), founded in 1998, is a high-tech biopharmaceutical company integrating research, development, production, and sales, with over 3,200 employees worldwide. Headquartered in the southern area of ​​Beijing’s Tongzhou Economic Development Zone, within the Zhongguancun National Independent Innovation Demonstration Zone, the company boasts an approximately 200,000 square meter industrial park.

As the first company in China to master the industrial production of recombinant insulin analogs, Gan & Lee Pharmaceuticals leads the Chinese diabetes market in the research and development and production of biosynthetic human insulin and its analogs. The company has established close collaborations with renowned companies such as Sandoz, a subsidiary of Novartis, and is actively expanding into overseas markets. As a global company dedicated to human health, Gan & Lee Pharmaceuticals upholds a culture of science and excellence, and is committed to providing high-quality products and services to people with diabetes worldwide.